Enzene Hands Romiplostim Biosimilar Programme to Adalvo, Will Keep Making It in Pune as Biologics CDMO
Swiss B2B pharma company Adalvo has acquired Pune-based Enzene’s romiplostim biosimilar programme referencing Amgen’s Nplate, while Enzene stays on as development and manufacturing partner and sharpens its focus on biologics CDMO services.
